A path to asthma control for different
patient types

Explore how DUPIXENT may help
control symptoms in different
types of patients.

Up to 84% of Adult Asthma Patients Present With Type 2 Inflammation1,2

Your appropriate patients with type 2 inflammation, which can be both systemic and local, may benefit from DUPIXENT today3-5

Clinical Presentation

  • 2 severe exacerbations in the past year
  • Diagnosed with asthma and chronic allergic rhinitis as a child
  • Positive perennial-aeroallergen skin test
  • Compromised lung function: 70% FEV1 % predicted
  • EOS: 155 cells/µL
  • IgE: 180 IU/mL

Treatment Goals

  • Wishes to engage in more physical activity without triggering an exacerbation and seeking nearby care
  • Hopeful to enjoy more activities with friends and family with less wheezing

Explore exacerbation data

Clinical Presentation

  • 2 severe exacerbations requiring SCS bursts
  • Diagnosed with adult-onset asthma at age 23
  • Negative test to allergens
  • Mucus hypersecretion with poor asthma control
  • Compromised lung function: 55% FEV1% predicted
  • EOS as high as 650 cells/µL

Treatment Goals

  • Hoping to reduce trips to the emergency department as a result of multiple exacerbations
  • Ready to enjoy more activities with less shortness of breath

Explore lung function data

Clinical Presentation

  • Experiences chest tightness and constant wheezing. Frequent exacerbation have led to multiple hospitalization
  • Diagnosed with adult-onset asthma at age 23
  • Has been prescribed courses of corticosteroids for her severe asthma over the past year, leading to the following6:
    • Feelings of anxiety and depression
    • Weight gain
    • Adult onset of diabetes
    • Hypertension

Treatment Goals

  • Hoping to reduce or eliminate OCS
  • Looking to control her asthma long term so she can spend more quality time with her family

Explore OCS-dependent data

Clinical Presentation

  • 2 exacerbation in the past year, requiring hospitalizations
  • Diagnosed with allergic rhinitis
  • Suffers from poor lung function, pontentially leading to impaired lung development
  • Currently receiving a burst of systemic corticosteroids, which are associated with lower height in adulthood, infection, and behavioral changes7
  • EOS: 610 cells/µL
  • IgE: 558 IT/mL

Treatment History

  • Despite high-dose inhaled steoids, he has missed multiple school days over the past year
  • Unable to try out for sport teams due to asthma symptoms
  • Family avoids engaging in physical activities while on vacation

Explore pediatric data

Patient profiles are representative and are not actual DUPIXENT patients.
Examples of patients with moderate-to-severe eosinophilic phenotype or with OCS-dependent asthma.
FEV1, forced expiratory volume in 1 second; SCS, systemic corticosteroid.